| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Revelation Biosciences, Inc.$1
+0.01 (+1.31%)
F 16Pipeline Score Richly Valued Biotech · Clinical
Market Cap
4.18 M
EPS
-39.47
P/E Ratio
-
Value Trade
71.35 K
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
1.38 M
Operating CF
-3.21 M
Total Assets
15.04 M
Total Liabilities
2.06 M
Equity
12.99 M
D/E Ratio
12,345
4.71 %
Week
-6.96 %
1 Month
-23.02 %
3 Month
-68.4 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
14.11 M
Monthly Burn
1.07 M
Runway
11.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
34.72 K
52 Week Range
0.88 - 30
% held by Insiders
4.1 %
% held by Institutions
12.79 %
Enterprise Value
-9.17 M
Total Shares
10.50 M
Short %
0.14 %
Float Shares
10.13 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Revelation Biosciences, Inc.
192Total events
0Upcoming
39Tier-1 (high impact)
2020 – 2026Coverage
Event history 192
May 7, 2026
▲FDA Feedback ReceivedGeminiFDA Meeting
Agreement with FDA on single adaptive Phase 2/3 study design for Gemini in AKI
acute kidney injurysource ↗
May 7, 2026
●Trial InitiationGeminiTrial
Initiated discussions with potential CROs for single adaptive Phase 2/3 study
acute kidney injurysource ↗
Mar 29, 2026
◆Oral PresentationGeminiPresentation
Presentation of new clinical data on Gemini for AKI and CKD at AKI & CRRT 2026
acute kidney injury (AKI) and chronic kidney disease (CKD)source ↗
Mar 29, 2026
▲Poster PresentationGeminiPresentation
Presented additional positive data analysis from PRIME Study at AKI & CRRT 2026
acute kidney injurysource ↗
Mar 2026
●Oral PresentationGeminiPresentation
Fireside chat at 38th Annual ROTH Conference
acute kidney injurysource ↗
Feb 26, 2026
●Quarterly UpdateCorporate
Financial results for three and twelve months ended December 31, 2025
Jan 28, 2026
Jan 21, 2026
▲SPA AgreementGeminiFDA Meeting
FDA agreement on approval pathway for Gemini in AKI
Acute Kidney Injury (AKI)source ↗
2026
◆Trial InitiationGeminiTrial
Initiation of Phase 2/3 study for Gemini in AKI
Acute Kidney Injury (AKI)source ↗
Drug Pipeline Intelligence
F16
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 13%
Micro Cap (rank 794 of 911)
Percentile RankRevelation Biosciences, Inc. has significant pipeline risk (16/100), with $59M risk-adjusted pipeline value, led by Gemini in Renal Insufficiency, Chronic (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gemini Small molecule | Renal Insufficiency, Chronic | Phase 1 | NCT06863467 | 8% | $59M | COMPLETED | 40 | - | - | Jul 22, 2025 | - | Oct 29, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Gemini | acute kidney injury and chronic kidney disease | — | 2026-01-15 | normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence Read More | Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) Read More | |
Gemini | acute kidney injury and chronic kidney disease | — | 2026-01-15 | normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence Read More | Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) Read More | |
Gemini | acute kidney injury and chronic kidney disease | — | 2026-01-15 | normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence Read More | Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in REVB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
REVB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
REVB▲ +1.3%today
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences has adopted a stockholder rights plan to protect its shareholders. This plan allows stockholders to realize the full value of their investments and reduces the risk of hostile takeovers. The rights will be exercisable if any person acquires 10% or more of the company's stock without board approval. The plan is designed to ensure fair evaluations of any potential acquisition offers.
Read more →REVBRevelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences has expanded its Acute Kidney Injury Advisory Board by adding Dr. Peter Pickkers and Dr. Lui Forni. This move aims to enhance the company's clinical strategy and improve patient outcomes as they prepare for a Phase 2/3 clinical trial of their treatment, Gemini. The board's expertise will help design effective studies addressing AKI.
Read more →REVB▼ -5.9%on this news
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences, Inc. reported its financial results for Q1 2026, highlighting a significant agreement with the FDA for a Phase 2/3 study of its product Gemini aimed at treating acute kidney injury. The company raised $6.7 million through a warrant inducement and presented positive data at a recent conference. However, it also reported a net loss of $3 million, which is higher than the previous year.
Read more →REVB▼ -5.7%on this news
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended
Revelation Biosciences, Inc. announced its financial results for the year ending December 31, 2025, reporting a net loss of $8.9 million. The company highlighted a positive outcome from its PRIME clinical study focused on chronic kidney disease and secured FDA agreement for an adaptive Phase 2/3 study for its product Gemini, aimed at treating acute kidney injury. Additionally, the company received $6.7 million through a warrant inducement, increasing its cash reserves to $10.7 million, projected to support operations into early 2027. Despite showing progress in clinical trials, the company continues to face significant financial losses.
Read more →REVBRevelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. announced a 1-for-4 reverse stock split effective January 28, 2026. This move is intended to boost the market price per share to meet Nasdaq's minimum bid requirements. The adjustment will apply uniformly to all stockholders, ensuring no change in their relative equity interests. The company continues to focus on its clinical programs.
Read more →REVB▼ -14.8%on this news· ran to -26% by day 3shared move
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Revelation Biosciences Inc. has announced the exercise of warrants, generating $11 million in gross proceeds. The company will issue up to 13,065,000 shares at a reduced price of $0.86 per share. Additionally, holders of the existing warrants will receive new Class J warrants, which can be exercised for more shares in the future. The transaction is expected to close by January 26, 2026.
Read more →REVBRevelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences has secured an agreement with the FDA for the approval pathway of Gemini, a treatment for Acute Kidney Injury (AKI). The agreement includes a composite endpoint of death and/or dialysis need and allows for a single Phase 2/3 adaptive study design. This development positions Gemini as a potential first-line therapy for AKI, addressing a significant unmet medical need.
Read more →REVBRevelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Inc. will present new clinical data on its product Gemini at the International Conference on Advances in Critical Care Nephrology in San Diego. The data highlights Gemini's potential to normalize hyperinflammation in CKD patients and its therapeutic benefits for acute kidney injury. This presentation marks a significant step in the company's strategy for advancing clinical studies.
Read more →REVBRevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 12, 2026
Revelation Biosciences announced an inducement grant of 90,000 restricted stock units to a new non-executive employee, approved by its Compensation Committee. This grant, made outside the company's equity incentive plan, is intended to encourage the employee's acceptance of the job. The RSUs will vest over two years, contingent on continued employment.
Read more →REVBTranscript of Corporate Update
The corporate update highlights the successful completion of a Phase 1b clinical study for Gemini in CKD patients, demonstrating promising results in managing inflammation. The company is in good financial standing and is preparing for a forthcoming FDA meeting to discuss the clinical and regulatory pathway for Gemini, particularly for treating acute kidney injury. Looking ahead to 2026, the company plans to build the necessary infrastructure for later-stage clinical studies, including manufacturing and investigator recruitment.
Read more →REVB▼ -6.5%on this news
Revelation Biosciences, Inc. Announces Financial Results for the three and nine months ended
Revelation Biosciences, Inc. announced its financial results for the third quarter of 2025, showing improvements in cash reserves and a notable reduction in net losses compared to the previous year's quarters. The company reported $12.7 million in cash, up from $6.5 million at the end of 2024, primarily from a public offering and warrant inducement. Positive results from the PRIME clinical study position the proprietary treatment, Gemini, favorably as they look to meet with the FDA regarding its clinical development. Despite these advancements, the company continues to face significant financial losses.
Read more →REVBRevelation Biosciences Inc. Announces Cancellation of Adjournment of
Revelation Biosciences Inc. announced the cancellation of its adjourned Special Meeting of Stockholders scheduled for October 29, 2025, due to technical difficulties that prevented shareholder voting. The company has set a new record date for a Special Meeting slated for December 3, 2025, and will issue new proxy materials to stockholders. This situation reflects ongoing challenges in effectively engaging stockholders and emphasizes the importance of clear communication in corporate governance.
Read more →REVBRevelation Biosciences Inc. Announces Adjournment of
Revelation Biosciences Inc. has announced the adjournment of its Special Meeting of Stockholders, initially scheduled for October 15, 2025, to October 29, 2025, due to insufficient shares present. This postponement allows additional time for stockholders to vote on critical proposals. The record date for voting remains September 11, 2025, and stockholders are encouraged to participate and vote. The meeting will be held virtually via webcast, ensuring accessibility for all shareholders.
Read more →REVB▼ -19%on this news· ran to -36% by day 3
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds San Diego, CA
Revelation Biosciences Inc. announced the exercise of warrants resulting in $9.6 million in gross proceeds. This transaction involves the immediate exercise of 4,355,000 shares at a price of $2.20 per share, bolstering the company's financial resources. Additionally, new Class I warrants will allow for the purchase of further shares in a private placement. The company plans to file a resale registration statement to facilitate this process.
Read more →REVB▼ -17.4%on this news· ran to -32% by day 3shared move
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study – Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini
Revelation Biosciences announced positive results from its Phase 1b PRIME clinical study, demonstrating that Gemini can significantly reduce inflammation in patients with stage 3 and 4 chronic kidney disease (CKD). The treatment met its primary endpoint of safety and tolerability while showing durable effects on inflammatory responses at the cellular level. Principal investigators indicated that these findings could mark a breakthrough for the treatment of CKD and potentially other inflammatory diseases. The company plans to discuss these results further during an upcoming webcast and is preparing for an End of Phase 1 meeting with the FDA.
Read more →REVB▼ -6.7%on this news
Revelation Biosciences, Inc. Announces Financial Results for the three and six months ended
Revelation Biosciences, Inc. has reported its financial results for the three and six months ended June 30, 2025, highlighting a net loss of $2.4 million for the quarter. The company successfully completed dosing for the PRIME Phase 1b Clinical Study and raised $4 million through a public offering. Cash reserves decreased, but the net loss has significantly improved compared to the prior year. Looking forward, Revelation anticipates announcing data from the Phase 1b study and aims to further develop its Gemini program.
Read more →REVB▲ +13.1%on this news· ran to +24% by day 3
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split effective
Revelation Biosciences, Inc. announced a 1-for-3 reverse stock split effective July 7, 2025, following stockholder approval. This measure is intended to augment the market price of the stock to comply with Nasdaq listing requirements. The company is also nearing the completion of enrollment in its Phase 1b clinical study for its product Gemini in chronic kidney disease patients, with topline data anticipated soon. Despite positive developments, the reverse stock split raises concerns about the stock's previous performance and ongoing clinical risk.
Read more →REVB▼ -54.4%on this news
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering San Diego, CA –
Revelation Biosciences, Inc. has announced a public offering of 3,640,000 shares at $1.10 each, aiming to raise about $4 million. The proceeds will finance the ongoing Phase 1b clinical study and support the development of other products and therapies. The offering is underwritten by Roth Capital Partners and is subject to customary closing conditions. It is noted that the company is focusing on addressing various health issues using its proprietary formulation, Gemini.
Read more →REVB▼ -6.2%on this news· ran to -66% by day 3shared move
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors San Diego, CA –
Revelation Biosciences has announced the retirement of George Tidmarsh, MD, PhD, from its Board of Directors due to potential conflicts of interest related to his new role at Stanford University. The company expressed gratitude for his guidance over the past five years and emphasized its ongoing commitment to developing therapies targeting inflammation. Meanwhile, positive Phase 1 clinical results for their product candidate, Gemini, were previously shared, indicating promising therapeutic potential. Tidmarsh's departure may influence board dynamics, creating uncertainties around future strategies.
Read more →REVB▲ +6.9%on this news
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended
Revelation Biosciences, Inc. reported its financial results for the quarter ending March 31, 2025, highlighting a focus on a new indication for Gemini and the completion of the first patient dosing in the PRIME Phase 1b study. The company has acknowledged a decrease in cash reserves to $3.7 million, with a net loss of $2.1 million for the quarter. Despite these challenges, Revelation is optimistic about the therapeutic potential of Gemini and anticipates topline data for its studies this summer.
Read more →REVB▼ -11.8%on this news
Gemini priming attenuates inflammation in human peripheral blood mononuclear cells – Observed response is excellent surrogate of the potential of Gemini in target indications – – Equivalent response
Revelation Biosciences announced that Gemini priming effectively reduces inflammation in human peripheral blood mononuclear cells. It is expected that this anti-inflammatory effect will be replicated in a Phase 1b clinical study involving chronic kidney disease (CKD) patients. This promising in vitro response suggests a potential efficacy of Gemini across various disease indications. Upcoming top-line data from the clinical study are anticipated by mid-2025, which will further inform the development of programs targeting acute kidney injury and post-surgical infection.
Read more →REVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended
Revelation Biosciences, Inc. reported its financial results for the year ended December 31, 2024, highlighting both challenges and achievements. The company announced the dosing of its first patient in the PRIME Phase 1b Clinical Study of Gemini, which has received FDA acceptance. However, the company also reported a significant decrease in cash reserves and substantial net losses compared to the previous year, raising concerns about its financial health moving forward. Despite the hurdles, the company aims to continue its operational momentum into 2025.
Read more →REVBRevelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval San Diego, CA –
Revelation Biosciences, Inc. has received continued approval for its common stock to be listed and traded on NASDAQ, demonstrating compliance with listing requirements. The company has initiated its PRIME Phase 1b clinical study, focusing on escalating doses of its product Gemini in patients with advanced Chronic Kidney Disease. CEO James Rolke emphasized the importance of NASDAQ listing for maintaining liquidity and attracting necessary resources for company growth. The results from the ongoing clinical study are anticipated to be communicated to shareholders at every milestone.
Read more →REVB▼ -7.8%on this news
Rebalancing inflammation to optimize health NASDAQ: REVB www.revbiosciences.com This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwar
Revolution Biosciences (REVB) recently presented updates on its Gemini platform, which aims to optimize treatments for various inflammatory conditions such as Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD). The results from early clinical trials have shown promising positive response biomarkers including IL-1RA and IL-10, indicating a robust induction. The company estimates that Gemini could tap into a market potential exceeding $18 billion. However, it also cautions investors about inherent risks in the drug development process and market competition.
Read more →REVBRevelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients – Dosing to Commence Mid-February – – Topline data expected Mid-Year – San Diego, CA –
Revelation Biosciences has initiated its PRIME Phase 1b clinical study of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The study will investigate escalating doses of the drug in a placebo-controlled setting with an expected enrollment of up to forty patients. Topline data, including safety and biomarkers, is anticipated by mid-year, which will help in further development of related treatment programs. Previous studies have demonstrated promising results for Gemini, highlighting its potential therapeutic benefits in CKD management.
Read more →REVBNasdaq Grants Revelation Biosciences Inc. Continued Listing San Diego, CA –
Revelation Biosciences Inc. has received confirmation from the Nasdaq Hearings Panel regarding its continued listing, contingent on maintaining stock prices above $1.00 for ten consecutive days by February 14, 2025. The company has also restored compliance with the Nasdaq's equity requirements after previously receiving a delisting notice. CEO James Rolke expressed gratitude for the panel's decision and mentioned focusing on the development of their drug, Gemini, which is set to enter Phase 1b trials for chronic kidney disease patients soon. Revelation successfully raised $4 million through warrants and anticipates initiating clinical studies in the first half of 2025.
Read more →REVB▲ +25%on this news· ran to -40% by day 3
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND -Phase 1b Study in CKD Patients to begin early 2025- San Diego, CA –
Revelation Biosciences Inc. has announced that the FDA has accepted its investigational new drug application for Gemini, a proposed treatment for chronic kidney disease (CKD). The acceptance marks a pivotal milestone for the clinical-stage company, allowing them to commence a Phase 1b study with up to 40 participants to evaluate Gemini's safety and effectiveness. The dual-ended study seeks to explore Gemini's impact on the innate immune response to stress associated with surgical procedures, which may subsequently reduce acute kidney injury in patient populations undergoing cardiac surgeries.
Read more →REVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended
Revelation Biosciences, Inc. reported its financial results for the three and nine months ended September 30, 2024, revealing significant financial challenges. Despite completing GMP manufacture of its Gemini drug supply and raising $3.8 million from warrant exercises, the company experienced a notable decrease in cash reserves and a substantial net loss of $13.3 million for the year. The company is advancing its Gemini drug platform, which is intended for multiple indications, but faces risks related to operational funding and ongoing clinical trials.
Read more →REVBRevelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 San Diego, CA –
Revelation Biosciences announced effective results from their clinical study of Gemini, showing significant dose-dependent increases in interleukin-10 (IL-10) levels. The findings, which include a 309-fold increase in the highest dosing group, affirm Gemini's capacity to modulate the immune response and promote healing. These results are consistent with prior preclinical studies suggesting the potential applications of Gemini in preventing acute kidney injury and managing chronic kidney disease. The company plans to proceed with a Phase 1b study in late 2024 to further investigate Gemini's therapeutic benefits.
Read more →REVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended
Revelation Biosciences, Inc. reported its financial results for the second quarter and first half of 2024, showcasing both progress and challenges. The company completed dosing in its phase 1 trial for Gemini, achieving positive safety and biomarker outcomes. Despite these advancements, Revelation disclosed a significant net loss of $8.4 million, raising concerns about its financial viability and operational expenses. The company has indicated that current cash reserves should sustain its operations through the end of 2024.
Read more →REVBASSIGNMENT FORM (To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby ar
The article outlines the assignment form for warrant shares of Revelation Biosciences, Inc. It details the procedure for exercising warrants and the required information that needs to be completed by the holder. The document serves as a formal request to convert warrants into shares, providing options for payment methods. Furthermore, it requires signatures and details to ensure proper transfer of ownership.
Read more →REVBGemini is a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic, detoxified version of lipopolysaccharide (LPS). PHAD stimulates TLR4 to precondition immune cells, including early, robust
Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), has shown promising results in improving kidney function and reducing tissue damage in a rat model of acute kidney injury (AKI). The treatment preconditions immune cells, leading to an attenuated pro-inflammatory response. In a study, pretreatment with Gemini significantly reduced serum levels of BUN and creatinine and reduced histopathological damage compared to controls. Phase 1 clinical studies for Gemini are scheduled to begin in February 2024.
Read more →REVBRevelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering San Diego, CA –
Revelation Biosciences Inc. announced a public offering of 1,365,000 shares of common stock and associated warrants, aiming to raise approximately $6.2 million. The proceeds will fund the development of multiple product candidates targeting surgical site infections and acute kidney injury, among other initiatives. The sale is expected to close around February 5, 2024, pending customary conditions. Roth Capital Partners is leading the offering as the sole placement agent.
Read more →REVBDeveloping innovative therapeutics to address unmet needs Corporate Presentation / January 2024 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Pr
Revelation Biosciences shared an updated corporate presentation highlighting its proprietary therapeutic pipeline focusing on unmet medical needs. The main product, Gemini, aims to prevent hospital-acquired infections and acute kidney injuries, with early Phase 1 studies anticipated in 2024. The company emphasizes the need for careful management of clinical trials and acknowledges various risks associated with its forward-looking statements. Positive preclinical data supports the potential effectiveness of its therapeutics, showcasing its relevance in addressing significant healthcare issues.
Read more →REVBDeveloping innovative therapeutics to address unmet needs Corporate Presentation / October 2023 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Pr
Revelation Biosciences provided an update on its therapeutic development pipeline in a recent corporate presentation, focusing on its proprietary formulation, Gemini. This therapeutic is designed to address unmet medical needs such as the prevention of hospital-acquired infections and acute kidney injury. Along with promising preclinical data, the company anticipates initiating a Phase 1 study in healthy volunteers by the end of 2023. However, there are several risks associated with clinical development that could impact the timeline and outcome of these endeavors.
Read more →REVBRevelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors San Diego, CA –
Revelation Biosciences Inc. has appointed Dr. Lakhmir Chawla to its Board of Directors, enhancing its leadership team with his extensive experience in nephrology and drug development. Dr. Chawla, previously the Chief Medical Officer at major pharmaceutical firms, aims to contribute to the development of innovative therapies for patients. His appointment follows the retirement of Curt LaBelle, M.D., who served on the Board for over two years. Company executives express confidence that Dr. Chawla will play a key role in advancing Revelation's mission and strategic initiatives.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended
Revelation Biosciences Inc. announced its financial results for the three and six months ended June 30, 2023, reporting a net income of $4.7 million. This is a notable recovery compared to a net loss of $8.5 million in the same period of 2022. The company's cash reserves increased significantly to $15.7 million, attributed to financing activities. Moreover, operating expenses decreased, showing improvements in financial management in comparison to the previous year.
Read more →REVBREMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders San Diego, CA –
Revelation Biosciences, Inc. has reminded stockholders to participate in the upcoming Annual Meeting scheduled for July 7, 2023. The company emphasizes the importance of stockholder votes regardless of the number of shares owned. In addition, Revelation is focused on developing immunologic-based therapies and has filed proxy materials with the SEC ahead of the meeting, providing crucial information for stockholders. The announcement underscores the company's commitment to transparency and shareholder involvement.
Read more →REVBRevelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to
Revelation Biosciences Inc. has announced the adjournment of its 2023 Annual Meeting of Stockholders from June 9, 2023, to July 7, 2023, due to insufficient attendance for constituting a quorum. The company encourages stockholders to vote and submit their proxies ahead of the meeting. Additionally, a proposal to ratify Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2023, has been added to the agenda. Stockholders must utilize revised proxy cards for the new proposal to be counted.
Read more →REVBDeveloping innovative therapeutics to address unmet needs Corporate Presentation / May 2023 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Privat
Revelation Biosciences presented an overview of its innovative therapeutic pipeline focused on addressing unmet medical needs. The company highlighted its proprietary PHAD formulations, which are expected to enter clinical trials for conditions like acute and chronic kidney diseases and healthcare-associated infections. Recent preclinical findings showed PHAD's efficacy in reducing renal injury and fibrosis. However, the company has cautioned investors about uncertainties related to future study enrollments and potential adverse effects as they advance their pipeline.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three Months Ended
Revelation Biosciences Inc. reported its financial results for Q1 2023 and highlighted substantial corporate progress. The company established a strong scientific advisory team and initiated further nonclinical studies for its therapies. Financially, Revelation reported a significant increase in cash reserves and achieved a net income of $6.2 million, marking a notable improvement compared to the previous year. The company anticipates starting its Phase 1 clinical studies for its main product candidates in Q4 2023.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended
Revelation Biosciences Inc. reported its financial results for 2022, highlighting a $15.6 million public offering and positive developments in its clinical pipeline. The company noted a reduced net loss of $10.8 million compared to $12 million in 2021. It plans to commence Phase 1a clinical studies for its product candidates REVTx-100 and REVTx-300 in the latter half of 2023. Additionally, Revelation's cash reserves increased significantly, indicating a strong financial position for ongoing operations.
Read more →REVBallergies. REVDx‑501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, eliminating the need for specialized instrumentation.
Revelation Biosciences Inc. has announced the pricing of a public offering comprising 3,225,000 shares along with associated warrants, aiming to raise approximately $15.6 million. The funding will be allocated towards advancing the development of several product candidates, specifically for clinical trials targeting surgical site infections and acute kidney injury. The offering is facilitated by Roth Capital Partners and is set to close subject to typical conditions. Although the public offering signals investor interest, there are inherent risks related to market conditions and competition faced by the company.
Read more →REVBRevelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective
Revelation Biosciences Inc. announced a 1-for-35 reverse stock split effective February 1, 2023, aiming to comply with NASDAQ listing requirements. This decision followed the approval at a Special Meeting of Stockholders held on January 30, 2023. Additionally, stockholders ratified an increase in authorized common stock to 500 million shares. The company intends to pursue further actions to meet the minimum stockholders' equity requirement moving forward.
Read more →REVBDeveloping innovative therapeutics to address unmet needs Corporate Presentation / January 2023 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Pr
Revelation Biosciences provides an update on its therapeutic development pipeline, focusing on products based on the immune-modulating activity of PHAD. The company aims to initiate Phase 1 clinical trials for REVTx-100 and REVTx-300 in 2023. Their therapeutic candidates target various healthcare-associated infections and inflammatory diseases. However, the company warns investors about the inherent risks of clinical development and potential market challenges.
Read more →REVBRevelation Biosciences Inc. Announces Pricing of Upcoming Automatic Unit Separation San Diego, CA –
Revelation Biosciences Inc. has announced the pricing for the upcoming mandatory separation of its trading units on January 13, 2023. Each unit consists of one share of common stock and one warrant for purchasing additional stock. This separation will transition the trading units off the Nasdaq Capital Market but allow the common stock and warrants to continue trading under their respective ticker symbols. The process is automatic and requires no action from the holders of the units, ensuring a seamless transition for investors.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress San Diego, CA November 10, 2022 Revelation Biosciences Inc. (NASDAQ: REVB) (the Company or Revelation ), a life sciences company that is f
Read more →REVBRevelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease - Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner - - Addi
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease - Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner - - Additional models of fibrotic diseases including AKI, CKD, NA
Read more →REVBDeveloping innovative therapeutics to address unmet needs Corporate Presentation / October 2022 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Pr
Developing innovative therapeutics to address unmet needs Corporate Presentation / October 2022 www.revbiosciences.com Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
Revelation Biosciences Inc. reported its financial results for Q2 2022, highlighting a significant increase in cash reserves to $3.5 million. The company is focused on advancing its product candidates, including therapies for allergies and chronic organ diseases. Despite a net loss of $8.5 million, Revelation expects its current funds to sustain operations through mid-2023.
Read more →REVBRevelation Biosciences Inc. Announces Closing of $5 Million Public Offering
Revelation Biosciences Inc. has successfully closed a public offering, raising approximately $5 million. The offering consisted of 8,333,334 shares of common stock at $0.60 per share, along with warrants. The company plans to utilize the proceeds for the development of its product candidates, including REVTx-99b, REVTx-200, and REVTx-300.
Read more →REVBRevelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
Revelation Biosciences Inc. has announced a public offering of 8,333,334 shares at $0.60 each, aiming to raise approximately $5 million. The funds will support the development of its lead candidate, REVTx-99b, and other therapies. The offering is expected to close around July 28, 2022, pending customary conditions.
Read more →REVBRevelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
Revelation Biosciences Inc. announced topline data from its Phase 1b CLEAR study of REVTx-99b for allergic rhinitis. While the primary endpoint regarding safety and tolerability was achieved, exploratory efficacy endpoints were not met, indicating no significant improvement in allergy symptoms or nasal flow compared to placebo. The study's results will inform future development decisions.
Read more →REVBRevelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today ann
Read more →REVBRevelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
SAN DIEGO, June 13, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today ann
Read more →REVBRevelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
Revelation Biosciences Inc. announced that the independent Safety Monitoring Committee has recommended the continuation of the Phase 1b clinical study for REVTx-99b, aimed at treating allergic rhinitis. The study, which is being conducted in Australia, is set to complete enrollment in the third quarter of 2022. The recommendation is seen as a significant milestone for the company and its lead drug candidate.
Read more →REVBRevelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today repo
Read more →REVBRevelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
Revelation Biosciences Inc. has announced an investor conference call scheduled for April 7, 2022, to provide a corporate update. The company is currently enrolling participants in its CLEAR study for REVTx-99b, with top-line results anticipated later this year. Additionally, discussions for partnering its REVDx-501 diagnostic asset are ongoing.
Read more →REVBRevelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection
Revelation Biosciences Inc. announced that its Phase 2b study of intranasal REVTx-99a for preventing H3N2 influenza did not meet its primary efficacy endpoint. The study, involving 30 healthy participants, showed no serious adverse events. Despite the results, the company remains committed to its other product candidates, including REVTx-99b for allergic rhinitis.
Read more →REVBRevelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development o
Read more →REVBRevelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announce
Read more →REVBRevelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development o
Read more →REVBin the Company's 8 - K dated 1/14/2022 and gr oss proceeds of $7.76M from the Company's recent PIPE details of which can be found in the Company's 8 - K filed on 1/27/2022. 2. Includes (i) 3,233,446 Petra Private Warrant
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / March 2022 www.revbiosciences.com Forward - Looking Statements This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of
Read more →REVBRevelation Biosciences Inc. to Present at the 34th Annual Roth Conference
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announce
Read more →REVBRevelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced
Read more →REVBRevelation Biosciences Raises $7.76 Million in Equity Financing
SAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced
Read more →REVBRevelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced
Read more →REVB▼ -27.2%on this news· ran to -52% by day 3shared move
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis
SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today ann
Read more →REVB▼ -7.9%on this news· ran to -51% by day 3shared move
shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K") filed with the Securities and Exchange Commission (the "SEC") on
UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION Capitalized terms used but not defined in this and Exchange Commission (the "SEC") on January 14, 2022 and, if not defined in the Form 8-K, included in the Company's effective proxy statement/prospectus
Read more →REVB▼ -19%on this news· ran to -51% by day 3shared move
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / January 2022 Forward - Looking Statements This presentation contains forward - looking statements as defined in the Priva
Developing innovative therapeutics and diagnostics to address unmet needs Corporate Presentation / January 2022 Forward - Looking Statements This presentation contains forward - looking statements as defined in the Private Securities Litigation Reform Act of 1995 , as amended .
Read more →REVBRevelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously announced SPAC merger closes, Revelation Biosciences, Inc. publicly listed on the NASD
Read more →REVBPetra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination -Agreements Provide Revelation with Capital to Fund Continu
Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Revelation Biosciences, Inc. Business Combination -Agreements Provide Revelation with Capital to Fund Continued Development of REVTx-99 for Respiratory Viral Infections- New York
Read more →REVBRevelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board
- Dr. Bellanti is Director of the International Center for Interdisciplinary Studies of Immunology and Professor of Pediatrics and Microbiology and Immunology at Georgetown University SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinic
Read more →REVBRevelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the site initiation for its
Read more →REVBRevelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board
- Dr. Catherine Blish is Professor of Medicine and Immunology and Associate Dean for Basic and Translational Research at the Stanford University School of Medicine – - Dr. Paul Spearman is Director of the Infectious Disease Division at Cincinnati’s Children’s Hospital Medical Ce
Read more →REVBRevelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today the initiation for its Phas
Read more →REVBRevelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID™
-REVID may have use by individuals in at-home settings for rapid monitoring of respiratory viral infections- -Offering broad detection of various viral infections, such as SARS-CoV-2, RSV, and influenza, institutions could potentially use REVID for mass screening and pre-PCR scr
Read more →REVBRevelation Biosciences Inc. Engages Destum Partners Inc. to Identify Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)
-Anti-viral nasal drop REVTx-99 has potential to broadly prevent or treat respiratory infections including influenza, SARS-CoV-2, rhinovirus, RSV and pneumonia- -Intranasal immunomodulator, REVTx‑200, would be used in combination with an intramuscular vaccination for more comple
Read more →REVBRevelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion
-Phase 1b study will investigate the efficacy of REVTx-99 on nasal symptoms elicited by nasal allergen challenge- -Top-line data anticipated in the first quarter of 2022- SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage lif
Read more →REVBRevelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
- Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported flu symptoms- - Top-line data anticipated in the second quarter of 2022 - SAN DIEGO, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation), a clinical-stage life
Read more →REVBTHIS PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENC
PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES AC
Read more →REVBRevelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded through a Merger with Petra Acquisition, Inc.
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded through a Merger with Petra NEW YORK, NY & SAN DIEGO, CA - August 30, 2021 - Revelation Biosciences, In
Read more →REVBPETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q New York, NY
PETRA ACQUISITION, INC. RECEIVES EXPECTED NASDAQ NOTIFICATION REGARDING DELAYED FORM 10-Q York, NY, June 1, 2021 - Petra Acquisition, Inc. (NASDAQ: PAIC) (the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, sha
Read more →REVBPETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING New York, NY
PETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING New York, NY, November 10, 2020 - Petra Acquisition, Inc. (NASDAQ: PAICU) (the "Company") announced today that separate trading of its shares of common stock and warrants underlying the Company's units
Read more →REVBPETRA ACQUISITION, INC. INDEX TO FINANCIAL STATEMENT PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 F- 1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING F
PETRA ACQUISITION, INC. INDEX TO FINANCIAL STATEMENT PAGE Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Shareholders and the Board of Directors of Petra Acquisition
Read more →REVBPetra Acquisition Inc. Announces Pricing of $70 Million Initial Public Offering New York, NY
Inc. Announces Pricing of $70 Million Initial Public Offering Oct. 08, 2020 (GLOBE NEWSWIRE) - Petra Acquisition, Inc. (Nasdaq: PAICU) (the "Company") announced today that its Registration Statement on Form S-1 (SEC File No. 333-240175) was declared effective by the Securities
Read more →Competitive Position
How REVB ranks across every disease it competes inCompetitive Position is a premium feature
See how REVB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial